Loan & DebtJun 22, 2026, 07:02 AM
Ligand to Offer $550M Convertible Senior Notes Due 2031
AI Summary
Ligand Pharmaceuticals announced its intention to offer $550.0 million in convertible senior notes due 2031 in a private placement, with an option for initial purchasers to buy an additional $82.5 million. A portion of the proceeds will be used to fund convertible note hedge transactions to offset potential dilution and to repurchase up to $75 million of common stock. The remaining funds are earmarked for general corporate purposes, including investments in complementary businesses.
Key Highlights
- Ligand to offer $550.0 million aggregate principal amount of convertible senior notes.
- Initial purchasers have a 13-day option to buy an additional $82.5 million in notes.
- Notes will mature on September 15, 2031.
- Up to $75 million of net proceeds will repurchase common stock from note purchasers.
- Proceeds will fund convertible note hedge transactions to reduce potential dilution.
- Remaining net proceeds are for general corporate purposes and investments.
Price Impact
More from LGND